UFT Dose Modification Based on Creatinine Clearance
No specific dose adjustments for UFT (tegafur-uracil) based on creatinine clearance are established in current guidelines or FDA labeling, but use with caution in patients with renal impairment.
Key Recommendations
Renal Function Considerations
The FDA drug label for UFT states to "use with caution in patients with renal impairment" but does not provide specific dose reduction algorithms based on creatinine clearance 1. This represents a significant gap in prescribing guidance compared to other fluoropyrimidines.
Practical Approach Based on Available Evidence
For patients with normal renal function (CrCl ≥60 mL/min):
- Standard dosing applies (typically 300-400 mg/day in divided doses)
- No adjustment needed
For patients with mild-to-moderate renal impairment (CrCl 30-59 mL/min):
- Consider dose reduction or increased monitoring
- The FDA label emphasizes caution but provides no specific reduction percentage 1
- Monitor for increased toxicity, particularly myelosuppression
For patients with severe renal impairment (CrCl <30 mL/min):
- Use with extreme caution
- Consider alternative agents if possible
- If UFT must be used, substantial dose reduction is prudent based on general fluoropyrimidine principles
Monitoring Strategy
Neutrophil counts are the most sensitive marker for UFT-related hematological toxicity and should be monitored closely 2. Recent research demonstrates that neutropenia appears earlier (day 3) than other cytopenias, making neutrophils the preferred monitoring parameter.
Recommended monitoring:
- Baseline: Complete blood count, renal function (serum creatinine, calculate CrCl)
- During treatment: CBC weekly for first month, then every 2 weeks
- Renal function: Monitor every 2-4 weeks, especially in patients with baseline impairment
Important Caveats
The evidence base is limited. Most clinical trials of UFT excluded patients with significant renal impairment or those aged >75 years 3. The lack of prospective data in renally impaired patients means dosing recommendations are largely extrapolated from:
- General fluoropyrimidine pharmacology: UFT is metabolized to 5-FU, which has renal elimination pathways
- Related agent data: Capecitabine requires dose modification for CrCl <50 mL/min 4, 1
- Clinical experience: The drug label's caution reflects post-marketing surveillance rather than controlled trials
Drug interactions matter. Avoid concurrent use with sodium-retaining medications in patients with renal impairment, as UFT contains sodium phosphate 1.
Comparison to Related Agents
Unlike UFT, capecitabine has established dose reductions for diminished creatinine clearance 4, 1. This suggests that oral fluoropyrimidines as a class require renal dose adjustment, even though UFT-specific data are lacking.
S-1 (a related oral fluoropyrimidine) has a validated dosing formula incorporating creatinine clearance, body surface area, and sex 5. While not directly applicable to UFT, this reinforces that renal function significantly impacts fluoropyrimidine exposure and toxicity.
Clinical Decision Algorithm
- Calculate baseline CrCl using Cockcroft-Gault formula
- If CrCl ≥60 mL/min: Use standard UFT dosing with routine monitoring
- If CrCl 30-59 mL/min: Reduce dose by 25-50% empirically; monitor neutrophils weekly initially
- If CrCl <30 mL/min: Strongly consider alternative therapy; if UFT essential, reduce dose by ≥50% with intensive monitoring
- Adjust based on toxicity: Hold for grade 3-4 neutropenia; resume at reduced dose when recovered
The absence of evidence-based dosing guidelines for UFT in renal impairment represents a significant limitation in clinical practice, necessitating cautious empiric dose reduction and vigilant monitoring.